Latigo Biotherapeutics, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Latigo Biotherapeutics, Inc. (LTGO) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 51.12 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-09-03.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-09-03
- 2026-06-30: Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month 51.12M shares.
- 2025-06-30: Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month 45.34M shares.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month |
|---|---|
| 2026-06-30 | 51.12M shares 10-Q · filed 2026-09-03 |
| 2025-06-30 | 45.34M shares 10-Q · filed 2026-09-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |